The VERV (Verv Therapeutics) swing trade has hit the 12.75 price target in the pre-market session for a 190% profit from the original entry on news of a buyout. Initial (May 7th) & updated daily chart (showing today’s pre-market trades in the white candlestick) below. Depending on your trading plan, consider booking partial or full profits and/or raising stops if holding out for the additional gains.
VERV daily May 7th
VERV daily June 17th
Eli Lilly (NYSE: LLY) has announced a definitive agreement to acquire Verve Therapeutics (Nasdaq: VERV), a clinical-stage biotech company specializing in genetic medicines for cardiovascular disease. The deal values Verve at $10.50 per share in cash ($1.0 billion), plus a CVR worth up to $3.00 per share, potentially reaching $13.50 per share ($1.3 billion total). Verve’s lead program, VERVE-102, is a first-in-class in vivo gene editing treatment targeting PCSK9 for cardiovascular disease, designed as a one-time treatment for conditions like heterozygous familial hypercholesterolemia (HeFH) and premature coronary artery disease. The FDA has granted Fast Track designation to VERVE-102, currently in Phase 1b trials. The acquisition price represents a 113% premium to Verve’s 30-day volume-weighted average trading price, with the deal expected to close in Q3 2025.